To further understand the clinical implications of mTOR in EGFR-mutant patients, we assessed baseline mRNA levels of MTOR by quantitative real-time polymerase chain reaction (qRT-PCR) in 57 EGFR-mutant erlotinib or chemotherapy treated NSCLC patients from the EURTAC trial from whom tumour tissue was available8. The gene discussed is MTOR; the disease is neoplasm.